Gastrinomas are the most common symptomatic, malignant pancreatic neuroendocrine tumor (pNET) in patients with or without MEN1 and sufficient numbers of these patients have been entered into our protocols to allow systematic assessment. Studies are now underway, evaluating the natural history of these tumors including the definition of factors determining prognosis and cause of death. Our studies have identified a cohort of 25% of patients in whom the gastrinomas have aggressive growth and 25% who have multiple endocrine neoplasia type 1 (MEN1). During this year information from our prospective studies was used to write five guideline and position papers dealing with the diagnosis of these tumors, treatment of advanced disease and pharmacological approach to management. Also two colloborative studies with Porf Ito, Kyushu University were done and are in press. One examining the epidemiology of pancreatic and GI neuroendocrine tumors in Japan with recent trends and a second the protential usefulness of serum Chromogranin A assays in Japan to identify patients with neuroendocrine tumors. Furthermore, chapters in both Goldman's and Harrison's textbooks of medicine as well as Yamada's and Sleisnger/Fordtran's Textbooks of Gastroentology were finished and are in press.

Project Start
Project End
Budget Start
Budget End
Support Year
23
Fiscal Year
2014
Total Cost
Indirect Cost
Name
U.S. National Inst Diabetes/Digst/Kidney
Department
Type
DUNS #
City
State
Country
Zip Code
Norton, Jeffrey A; Krampitz, Geoffrey W; Poultsides, George A et al. (2018) Prospective Evaluation of Results of Reoperation in Zollinger-Ellison Syndrome. Ann Surg 267:782-788
Ito, Tetsuhide; Lee, Lingaku; Jensen, Robert T (2018) Carcinoid-syndrome: recent advances, current status and controversies. Curr Opin Endocrinol Diabetes Obes 25:22-35
Capdevila, Jaume; Bodei, Lisa; Davies, Philippa et al. (2018) UNMET MEDICAL NEEDS IN METASTATIC LUNG AND DIGESTIVE NEUROENDOCRINE NEOPLASMS. Neuroendocrinology :
Lee, Lingaku; Ito, Tetsuhide; Jensen, Robert T (2018) Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies. Expert Rev Anticancer Ther 18:837-860
Lee, Lingaku; Ito, Tetsuhide; Jensen, Robert T (2018) Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence. Expert Opin Pharmacother 19:909-928
Norton, Jeffrey A.; Foster, Deshka S.; Blumgart, Leslie H. et al. (2018) Incidence and Prognosis of Primary Gastrinomas in the Hepatobiliary Tract. JAMA Surg 153:e175083
Lee, Lingaku; Ito, Tetsuhide; Igarashi, Hisato et al. (2018) Dose and schedule modification are required for long-term continuation of sunitinib in Japanese patients with advanced pancreatic neuroendocrine tumors. Cancer Chemother Pharmacol 81:163-169
Foster, Deshka S; Jensen, Robert; Norton, Jeffrey A (2018) Management of Liver Neuroendocrine Tumors in 2018. JAMA Oncol :
Ueda, Keijiro; Kawabe, Ken; Lee, Lingaku et al. (2017) Diagnostic Performance of 48-Hour Fasting Test and Insulin Surrogates in Patients With Suspected Insulinoma. Pancreas 46:476-481
Jensen, Robert T; Norton, Jeffrey A (2017) Treatment of Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1: Some Clarity But Continued Controversy. Pancreas 46:589-594

Showing the most recent 10 out of 58 publications